VEGFA and endophthalmitis: Current anti-VEGF drugs, injected intravitreally to bypass the anterior and posterior access barriers, have serious associated risks, such as retinal tear/detachment [11,12], endophthalmitis, cataracts, vitreous and retinal hemorrhage, choroidal rupture, leakage into the fellow eye, and increased risk of neurological disabilities [13,14,15,16].